10 September 2018
A new report by visiongain forecasts the overall world market for human antibacterial treatments will reach $44.13bn in 2020. That revenue prediction and others appear in Antibacterial Drugs: World Industry and Market Prospects 2016-2026, published in March 2016.
This study also analyses qualitative issues affecting the antibacterial drug market from 2015, with recent events, opinions and predictions. Governmental incentives, clinical trial guidelines, treatment resistance, and many other forces are discussed. The result is a quantitative and qualitative analysis of the antibacterial industry and market, showing commercial potentials of those drugs from 2016 to 2026.
From 2015, new therapies and high medical needs encourage investments, developments, wider treatment and higher sales from bacteria-treating medicines. The new study discusses commercial potentials of human antibiotics and their producers. That investigation gives multilevel revenue forecasting to 2026. It shows predictions and discussions planners, organisers and leaders need. Visiongain is a business information publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials. Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “The growth of the antibacterial drug market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market. Current leading drugs will lose patent exclusivity from 2015 to 2026 thus opening opportunities for generics which will lead to a drop in market value. The uptake of new drugs launched within the second half of the forecast period however will stimulate that revenue growth. The overall antibacterial drug market is expected to grow with a CAGR of 2.5% from 2020-2026.”
That updated investigation shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It forecasts six antibiotic classes:
• Cephalosporins • Penicillins • Fluoroquinolones • Macrolides • Carbapenems • Other medicines for treating bacterial infections.
Those analyses forecast the revenues of 43 leading antibacterial drugs from 2016 to 2026, including Zyvox, Cubicin, Augmentin, Zosyn/Tazocin, Avelox, Invanz and generic amoxicillin. The new survey also discusses antibacterial agents in clinical trials, examining research and development.
That report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU, Germany, France, the UK, Spain, Italy, Japan, Brazil, Russia, India, China and South Korea. That study also contains three interviews with other authorities on antimicrobial medicines.
Antibacterial Drugs: World Industry and Market Prospects 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Those studies analyse pharmaceuticals, medical devices, diagnostics and contract services, showing their technological, clinical and commercial potentials.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.